Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre , Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Inadequately Controlled Cancer-related Pain

NCT00725114 is registered in ClinicalTrials.gov with Wex Pharmaceuticals Inc. as lead sponsor.

NCT NCT00725114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00725114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre , Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Inadequately Controlled Cancer-related Pain
Lead sponsor
Wex Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
November 30, 2012
Enrollment
165 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pain